| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 03-05-2024 | 12-31-2023 | 10-K | |
| 2 | 11-13-2023 | 09-30-2023 | 10-Q | |
| 3 | 08-28-2023 | 06-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...
The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting unde...
Jefferies analyst Akash Tewari maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $37 t...
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded do...
Stifel analyst Akash Tewari maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $46 to $95.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...
